FDG-PET Findings Research Articles

Estadificación del cáncer de pulmón de células no pequeñas. Utilidad de la imagen estructural (TAC) y funcional (FDG-PET)

To evaluate diagnostic accuracy of FDG-PET in the definition of non-small cell lung cancer (NSCLC) and analyze diagnostic validity of CT scan and FDG-PET in its staging. Patients with clinical suspicion of potentially resectable NSCLC (n = 108) were studied by standard procedures in our setting, including fibrobronchoscopy, transthoracic fine-needle aspiration, thoracoabdominal CT scan and FDG-PET. Gold standard was histopathological study in patients who underwent surgery and by specific imaging methods and biopsy, when available, in patients who did not. In 13% of patients, the FDG-PET findings were negative and no tumor was observed in the histological study of the piece. In 22% of patients, FDG-PET detected metastatic disease (M0 by CT scan). For mediastinal involvement, global diagnostic accuracy was 0.90 with FDG-PET and 0.59 with CT scan. False positive FDG-PET findings were produced by inflammatory conditions and false negative findings by the small size or proximity of lymph nodes to primary tumor. Mediastinal staging by CT scan and FDG-PET was correct in 56% and 87% of patients, respectively. Although complementary, the functional method (FDG-PET) is significantly superior to the structural method (CT) for detection of mediastinal tumor disease.

FDG-PET in the Serial Assessment of Patients with Lymphoma in Complete Remission.

FDG-PET role in the assessment of lymphoma patients is well established but only few papers evaluated the usefulness of FDG-PET during follow up.Aim: to prospectively investigate the value of serial FDG-PET scans in the follow up of lymphoma patients in complete remission. All lymphoma patients who achieved a complete remission were prospectively enrolled in the study and scheduled for serial FDG-PET scans at 6, 12, 18 and 24 months; further scans were then carried out on annual basis (overall 421 pts, 160 pts with Hodgkin's Disease (HD) and 261 pts with non-Hodgkin Lymphoma (NHL) were studied). All patients had a final assessment using other imaging procedures and/or biopsy and/or clinical evolution. FDG-PET findings were reported as positive, indeterminate or negative for relapse; after comparison with all available data, PET results were categorized as true positive (TP), true negative (TN), false positive (FP), indeterminate turned out to be relapse (I+) and indeterminate turned out to be complete remission (I-).Results: PET documented relapse in 42 cases at 6 mo (14 HD (8.8%) and 28 NHL (10.7%); in 31 cases at 12 mo (14 HD (9.5%) and 17 NHL (7.3%); in 27 cases at 18 mo (6 HD (4.5%) and 21 NHL (3.2%); in 9 cases at 24 mo (3 HD (2.4%) and 6 NHL (3.2%); and in 5 cases at > 36 mo (2 HD (2.8%) and 3 NHL (6.5%). Out of 125 scans reported as positive for relapse, 109 turned out to be TP (PPV of 87%); no false negative scan was recorded, and in the great majority of cases PET detected the presence of relapse before clinical evidence. Our results confirm that FDG-PET is a valid tool for lymphoma patients follow-up. The higher incidence of relapse occurred in both HD and NHL quite early after complete remission (at 6 and 12 months for HD and at 6, 12 and 18 months for NHD), thus confirming the usefulness of performing FDG-PET scans at these times in order to identify recurrence. The role of serial PET at later times (after 18 months for HD and 24 months for NHL) was found less relevant.

Lymphadenopathy Due to Amyloidosis Secondary to Sjögren Syndrome and Systemic Lupus Erythematosus Detected by F-18 FDG PET

We report a case showing lymphadenopathy due to amyloidosis secondary to Sjögren syndrome and systemic lupus erythematosus (SLE). The amyloid lymphadenopathy was detected by positron emission tomography (PET) as faint but significant uptake of F-18 fluorodeoxyglucose (FDG). Lymph node amyloidoses after SLE are probably unusual, and those secondary to Sjögren syndrome remain rare. FDG-PET findings of amyloidosis have been exclusively described with pulmonary amyloidomas. When a patient with a connective tissue disease develops significant FDG uptake in the lymph nodes, the possibility of amyloidosis should be considered.

Value of PET in the Assessment of Patients with Neurofibromatosis Type 1

The objective of our study was to investigate the use of PET in the detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1 (NF1). Forty-five patients with NF1 who underwent whole-body PET for suspected MPNST based on clinical symptoms or radiologic examinations were retrospectively evaluated. Ten patients underwent additional carbon-11 (11C) methionine PET because of equivocal 18F-FDG PET findings or because of a discrepancy between the FDG PET and clinical findings. PET images were evaluated for the distribution and uptake pattern, and the standardized uptake values (SUVs) were obtained. Twenty-seven patients underwent biopsy or surgery of the detected lesions and 18 patients were followed up clinically and with repeat imaging studies. Fifty lesions were identified on FDG PET. There were eight false-positive results and one false-negative on FDG PET. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FDG PET in detecting MPNSTs in patients with NF1 were 95%, 72%, 71%, 95%, and 82%, respectively. Using 11C methionine PET in combination with FDG PET reduced the number of false-positive results from eight to two, which increased the specificity from 72% to 91%. In five patients, 11C methionine FDG PET contributed additional information about nontarget lesions that influenced treatment planning. FDG PET is a sensitive technique in the detection of MPNSTs in patients with NF1. The addition of 11C methionine PET increases specificity in equivocal cases. PET may improve preoperative tumor staging by detecting metastases or second primary tumors, which often are present in patients with NF1.

Discrepancy between magnetic resonance and 18F-fluorodeoxyglucose positron emission tomography imaging in a case of borderline ovarian tumor

Borderline ovarian tumors have a far more favorable clinical course compared to malignant ovarian tumors. To date, the role of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for the differentiation of an ovarian mass remains controversial. Discrepancy between FDG-PET and magnetic resonance (MR) images is rare but may cause a serious dilemma in decision-making. We report a case of a borderline ovarian tumor showing discrepancy between MR and FDG-PET findings. FDG-PET findings may help with the differentiation of ovarian masses when clinical findings are not coincidental.

SPECT und PET in der Diagnostik von Epilepsien

In preoperative localisation of epileptogenic foci, nuclear medicine diagnostics plays a crucial role. FDG-PET is used as first line diagnostics. In case of inconsistent MRI, EEG and FDG-PET findings, 11C-Flumazenil-PET or ictal and interictal perfusion-SPECT should be performed. Other than FDG, Flumazenil can help to identify the extend of the region, which should be resected. To enhance sensitivity and specificity, further data analysis using voxelbased statistical analyses or SISCOM (substraction ictal SPECT coregistered MRI) should be performed.

Extensive FDG uptake and its modification with corticosteroid in a granuloma rat model: an experimental study for differentiating granuloma from tumors

Increased (18)F-fluorodeoxyglucose (FDG) uptake in inflammatory lesions, particularly in granulomatous inflammation (e.g., sarcoidosis), makes it difficult to differentiate malignant tumors from benign lesions and is the main source of false-positive FDG-PET findings in oncology. Here, we developed a rat granuloma model and examined FDG uptake in the granuloma. The effects of corticosteroid on FDG uptake in the granuloma were compared with those in a malignant tumor. Rats were inoculated with Mycobacterium bovis bacillus Calmette-Guérin (BCG) or allogenic hepatoma cells, and subdivided into control and pretreated (methylprednisolone acetate, 8 mg/kg i.m.) groups. Radioactivity in tissues was determined 1 h after the FDG injection. FDG-PET was performed in rats bearing BCG granulomas or tumors before and after prednisolone treatment. Mature epithelioid cell granuloma-formation and massive lymphocyte-infiltration were observed in the control group of granuloma, histologically similar to sarcoidosis. The mean FDG uptake in the granuloma was comparable to that in the hepatoma. Prednisolone reduced epithelioid cell granuloma-formation and lymphocyte-infiltration. Prednisolone significantly decreased the level of FDG uptake in the granuloma (52% of control), but not in the hepatoma. The FDG uptake levels in the granulomas and tumors were clearly imaged with PET. We developed an intramuscular granuloma rat model that showed a high FDG uptake comparable to that of the tumor. The effect of prednisolone pretreatment on FDG uptake was greater in the granuloma than in the tumor. These results suggest that BCG-induced granuloma may be a valuable model and may provide a biological basis for FDG studies.

A 18F-FDG-positive, 67Ga-negative, and transferrin receptor expression-negative patient with diffuse large B-cell lymphoma

We recently experienced a case with uveitis suffering from fever of unknown origin suspected of being caused by sarcoidosis. Chest computed tomography showed right supraclavicular, bilateral mediastinal, and right hilar lymphadenopathy, and intensive abnormal uptake of 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) was observed on positron emission tomography with 18F-FDG (FDG-PET). On the other hand, 67Ga scintigraphy showed almost no abnormal findings. Histopathological examination revealed the lesion to be a diffuse large B-cell lymphoma (DLBCL), namely, an aggressive non-Hodgkin lymphoma from a right supraclavicular lymph node biopsy specimen. Additional immunohistochemical analysis showed the negative expression of transferrin receptor (TfR) on the formalin-fixed paraffin-embedded specimen. Although DLBCL is generally considered to be a 67Ga-avid tumor, it does not always have a large number of TfRs and that leads to a discrepancy between the 67Ga scintigraphy and FDG-PET findings. FDG-PET should be more appropriate for the initial staging of DLBCL than 67Ga scintigraphy, whereas 67Ga scintigraphy might be able to provide additional information including prognostic factors and to support strategies that target TfR for cancer therapy.

Stereotactic cortical resection in non-lesional extra-temporal partial epilepsy

The presentation and treatment of a patient with extra-temporal non-lesional partial epilepsy is discussed herein. His clinical semiology was consistent with supplementary motor area seizures; however, MR imaging did not demonstrate a lesion. A region of stable cortical glucose hypermetabolism in the left frontal region was noted with 2-fluoro-2-deoxy-D-glucose (FDG)-PET. This was consistent with the frequent interictal discharges evident over the left fronto-temporal region and the stereotypic high amplitude ictal discharges arising with highest amplitude from the left frontal region. Epileptiform activity evident on an intracranial 64-point subdural recording grid placed over the left dorsolateral frontal cortex confirmed a distribution concordant with FDG-PET findings. The subsequent resection was guided by the PET and EEG findings rather than structural MR imaging, and a limited cortical resection led to an immediate and substantial reduction in seizure frequency.

F-18 FDG PET/CT imaging of low-grade mucoepidermoid carcinoma of the bronchus

Mucoepidermoid carcinomas in the bronchial tree are extremely rare tumors. Such tumors are classified into low-grade and high-grade on the basis of histological criteria. Fluorine-18-fluorodeoxyglucose positron emission tomography (F-18 FDG PET) is a useful technique for the evaluation of pulmonary lesions; however, to our knowledge, F-18 FDG PET findings in mucoepidermoid carcinoma of the bronchus have been described in only a few cases. Identifiable focal F-18 FDG uptake has been reported in high-grade mucoepidermoid carcinoma, but it is unclear whether F-18 FDG accumulates in low-grade mucoepidermoid carcinoma. Here, we present the case of a 37-year-old woman, with pathologically proven low-grade mucoepidermoid carcinoma, who underwent high-resolution computed tomography (CT) and F-18 FDG PET/CT before treatment.

Chemotherapy-Induced Normalization of FDG Uptake by Colorectal Liver Metastases Does Not Usually Indicate Complete Pathologic Response

Dramatic responses are being observed in colorectal cancer liver metastases treated with newer chemotherapeutic regimens. These have been associated with normalization of [18F]fluoro-2-deoxy-d-glucose (FDG) uptake (complete metabolic response) on follow-up Positron Emission Tomography with [18F]fluoro-2-deoxy-d-glucose (FDG-PET) scans in some patients. It is unclear how often complete metabolic response is indicative of complete tumor destruction. We analyzed a subset of patients who had neoadjuvant chemotherapy for hepatic metastases from colorectal adenocarcinoma. Inclusion criteria were: (1) FDG-avid hepatic lesions before initiation of chemotherapy; (2) complete metabolic response of the same lesions after chemotherapy; and (3) histopathologic examination of hepatic lesions. Complete pathologic response was defined as no histologically identifiable viable tumor. Fourteen patients fit the inclusion criteria. All had synchronous, hepatic-only colorectal metastases. On microscopic examination, complete pathologic response to the neoadjuvant regimen was found in only 5 of 34 lesions (15%) and in only 3 of the 14 patients (21%). Seven lesions had complete metabolic response and disappeared on computed tomography (CT); of these, six still contained viable tumor. We conclude that complete metabolic response on FDG-PET after neoadjuvant chemotherapy is an unreliable indicator of complete pathologic response. Therefore, currently, curative resection of liver metastases in these patients should not be deferred on the basis of FDG-PET findings.

Positron emission tomography with 18F-fluorodeoxyglucose in patients with uterine sarcoma

Objective To describe our experience with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), in patients with uterine sarcomas, both under suspicion of recurrence and in tumour staging as an incidental pathology finding after hysterectomy. Material and methods A retrospective review of FDG-PET performed in 10 patients with clinical diagnosis of uterine sarcoma (7 patients with suspicion of recurrence and three for initial staging) was carried out between April 2002 and January 2006. Mean age was 52.2 years. The time of evolution after initial diagnosis varied from one month to 15 years (median time: 14 months). Lesions were classified as 8 leiomyosarcomas and 2 carcinosarcomas. FIGO staging classified 5 patients as stage I, 1 patient as stage III, and 4 patients as stage IV. Results In 4 of 7 patients with suspicion of recurrence, there were discrepancies between the information provided by positron emission tomography (PET) and conventional imaging techniques (CIT). FDG-PET was negative in three cases of inconclusive CAT. PET was negative in one case with pulmonary metastases. There was concordance between the FDG-PET and CIT findings in the 3 staging studies. Pathological confirmation was obtained in 5 cases, with a mean follow-up time of 14 months. Conclusions FDG-PET may be useful in the follow up of uterine sarcoma patients and when the tumour is an incidental finding in hysterectomy for other causes.

Adenomyomatosis of the Gallbladder: Another Cause for a “Hot” Gallbladder on 18F-FDG PET

WEB This is a Web exclusive article. tudies of small numbers of patients have shown that 18F-FDG PET is useful in differentiating benign from malignant lesions within the gallbladder [1, 2]. However, a limitation of FDG PET is that inflammatory conditions with increased glucose metabolism cannot be distinguished from neoplasms because those conditions also show increased uptake of the agent. We present a patient with increased activity within the fundus of the gallbladder on an FDG PET scan obtained for staging of colon carcinoma. Pathologic examination of the gallbladder showed focal adenomyomatosis with no evidence of malignancy. Adenomyomatosis of the gallbladder and the resulting chronic inflammation can lead to false-positive FDG PET findings.

Changes in Glucose Metabolism in Cerebral Cortex and Cerebellum Correlate With Tremor and Rigidity Control by Subthalamic Nucleus Stimulation in Parkinson’s Disease: A Positron Emission Tomography Study

Objective. Employing [(18) F]fluorodeoxyglucose (FDG) positron emission tomography (PET) to assess the correlation between the effect of deep brain stimulation (DBS) on the subthalamic nucleus (STN) and the regional cerebral metabolic rate of glucose (rCMRGlc) in advanced Parkinson's disease patients (N=8). Materials and Methods. On the basis of patients' diary records, we performed FDG-PET during the off-period of motor activity with on- or off-stimulation by STN-DBS on separate days and analyzed the correlation between changes in motor symptoms and alterations in the rCMRGlc. Result. When FDG-PET was performed, the motor score on the unified Parkinson's disease rating scale (UPDRS) was 64% lower with on-stimulation than with off-stimulation (p<0.001, Wilcoxon single-rank test). STN-DBS increased the rCMRGlc in the posterior part of the right middle frontal gyrus, which corresponded to the premotor area, and the right anterior lobe of the cerebellum (p<0.005, paired t-test). No region exhibited a decrease in rCMRGlc. Among the items of the UPDRS motor score, the changes in resting tremor and rigidity of the left extremities showed a significant correlation with the changes in rCMRGlc observed in the right premotor area (p<0.02 and p<0.05, respectively, Spearman's rank correlation). Conclusions. STN-DBS either activates the premotor area or normalizes the deactivation of the premotor area. These FDG-PET findings obtained are consistent with the idea that STN-DBS modifies the activities of neural circuits involved in motor control.

Imaging of Lower Extremity Artery Atherosclerosis in Diabetic Foot

In this communication, we present the FDG-PET findings in 2 patients with Type II diabetes mellitus with foot complications. The first case was a 47-year-old female patient, diagnosed case of a diabetic foot with ischemic complications and the second was a 60-year-old female patient diagnosed to have a neuropathic Charcot foot. Although the first case demonstrated prominent diffuse uptake in the lower extremity arteries, including popliteal and tibial arteries, the other did not. Histopathological correlation was available in both cases: the case showing diffuse FDG uptake in the arteries revealed features of atherosclerosis along with evidence of a gangrenous right toe; the other case without any uptake in the arteries had no evidence of atherosclerosis in the pathologic examination. However, increased tracer uptake was noted in the distal left tibia just above the ankle, midshaft of the tibia as well as in the soft tissue of lateral and plantar aspect of the left foot which was suggestive of osteomyelitis and cellulites, respectively, consequent to the neuropathy. FDG-PET is being actively investigated for its potential to image atherosclerosis. The present report describes its application for assessing inflammation related to atherosclerosis in a diabetic foot with ischemic complications and has important implications for clinical management because making a distinction between diabetic neuropathy and angiopathy is critical for therapeutic intervention in these patients. It is worthwhile to consider a larger prospective trial on the role of FDG-PET in this setting.

Clinicopathological features in correlation with epidermal growth factor receptor gene mutations in non-small cell lung cancer (NSCLC)

21148 Background: Mutations in the epidermal growth factor receptor (EGFR) gene are found in 10–30% of non-small cell lung cancer, and are useful to predict the efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib. However, it is sometimes difficult to examine such mutations. Thus, prediction of presence or absence of EGFR mutations, correlated with clinical response to EGFR-TKIs, based on clinicopathological characteristics may be important in clinical practice. Methods: We retrospectively assessed EGFR-mutation status in correlation with clinical features including FDG-PET findings and pathological features including presence or absence of bronchioalveolar component (BAC) in adenocarcinoma (Ad) case. A total of 72 consecutive patients (24 females; mean age, 65 years; 40 Ad cases) who received thoracotomy from August 2005 through October 2006 were reviewed Results: Sixteen cases (22%) had EGFR-mutations (8 cases each in exon 19 and exon 21). The incidence of EGFR-mutation was significantly higher in female (42%) or never-smoker (60%) than in male (13%) or smoker (15%). EGFR-mutation was almost exclusively found in Ad; among Ad cases, there was no significant difference in the incidence of EGFR-mutation between BAC-positive (47%) and BAC-negative cases (29%; p=0.33). Among 61 cases who received FDG-PET scan prior to thoracotomy, only 15% of EGFR- mutated cases had higher FDG-uptake, whereas 47% of EGFR-wild cases had higher FDG-uptake (p=0.36); the sensitivity and specificity of lower FDG-uptake to predict the presence of EGFR-mutations were 71% and 53%, respectively. The positive predictive value (PPV) of lower- FDG-uptake for the presence of EGFR-mutations was only 29%, but the negative predictive value (NPV) was as high as 85%. The mean standardized uptake value (SUV) of FDG for EGFR-wild patients and EGFR-mutated patients were 5.7 and 3.3, respectively (p=0.11). The mean SUV for tumors mutated in exon 19 seemed to be lower than that for tumors mutated in exon 21 (1.8 versus4.6). Conclusions: Higher FDG-uptake combined with clinical features (male and smoker) may help to exclude patients with EGFR-wild tumors who may not respond to EGFR-TKIs treatment. No significant financial relationships to disclose.

Primary Hepatic Angiosarcoma on Coregistered FDG PET and CT Images

4Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan. ngiosarcoma is an uncommon mesenchymal malignant neoplasm of the vascular or lymphatic endothelium, accounting for 2% of all soft-tissue sarcomas [1–4], that can affect any organ but seems to have a predilection for the skin in the head and neck regions [3, 4]. Although primary hepatic angiosarcoma is rare and accounts for only 2% of primary hepatic tumor, it is the most common malignant mesenchymal tumor of the liver [5]. Various appearances of primary hepatic angiosarcoma on CT and on MRI have been noted [3, 5]. However, to the best of our knowledge, the FDG PET findings have not been described yet. Here, we present a case of primary hepatic angiosarcoma and the coregistered FDG PET and CT images that show the affected sites.

Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection?

This paper is based on the results from an ongoing prospective trial designed to investigate the usefulness of FDG PET in the complicated diabetic foot. To investigate the potential utility of FDG PET imaging in the setting of acute neuropathic osteoarthropathy (Charcot's foot). A total of 63 patients, in four groups, were evaluated. The groups were: (A) 17 patients with a clinical diagnosis of Charcot's neuroarthropathy (11 men, six women; mean age: 59.4+/-8.6 years); (B) 21 patients with uncomplicated diabetic foot (16 men, five women; mean age: 63+/-10 years); (C) 20 non-diabetic patients with normal lower extremities (12 men, eight women; mean age 54+/-19 years); and (D) five patients with proven osteomyelitis secondary to complicated diabetic foot (three men, two women; mean age: 61.2+/-13.9 years). Five patients in group A had foot ulcer and intermediate to high degree of suspicion for superimposed osteomyelitis. Each subject underwent FDG PET imaging of the lower extremities in addition to MRI and the findings were compared with the final diagnostic outcome based on histopathology and clinical follow-up. The images were examined visually for focal abnormalities. Regions of interest were assigned to the sites of abnormal FDG uptake for calculating maximum standardized uptake value (SUVmax). Two important clinical decision-making issues were explored: (1) whether FDG PET shows a definitive uptake pattern in Charcot's neuroarthropathy and if so whether that could be utilized to differentiate it from other complicated forms of diabetic foot like osteomyelitis and cellulitis, which is frequently a diagnostic challenge in this clinical setting; and (2) how accurate FDG PET is in detection soft tissue infection in patients with Charcot's foot. These issues were examined by utilizing FDG PET findings along with MRI results in the same patient. We observed a low degree of diffuse FDG uptake in the Charcot's joints. This was clearly distinguishable from the normal joints. The SUVmax in the Charcot's lesions varied from 0.7 to 2.4 (mean, 1.3+/-0.4) while those of midfoot of the normal control subjects and the uncomplicated diabetic foot ranged from 0.2 to 0.7 (mean 0.42+/-0.12) and from 0.2 to 0.8 (mean 0.5+/-0.16), respectively. The only patient with Charcot's foot with superimposed osteomyelitis had an SUVmax of 6.5. The SUVmax of the sites of osteomyelitis as a complication of diabetic foot was 2.9-6.2 (mean: 4.38+/-1.39). Unifactorial analysis of variance test yielded a statistical significance in the SUVmax between the four groups (P<0.01). The SUVmax between the normal control groups and the uncomplicated diabetic foot was not statistically significant by the Student's t-test (P>0.05). In the setting of concomitant foot ulcer FDG PET accurately ruled out osteomyelitis. Overall sensitivity and accuracy of FDG PET in the diagnosis of Charcot's foot was 100 and 93.8%, respectively; and for MRI were 76.9 and 75%, respectively. FDG PET showed foci of abnormally enhanced uptake in the soft tissue which was suggestive of inflammation in seven cases (43.75%) which were proven pathologically to be secondary to infection. In only two of these cases the features of soft tissue infection were noted on the magnetic resonance images. The results support a valuable role of FDG PET in the setting of Charcot's neuroarthropathy by reliably differentiating it from osteomyelitis both in general and when foot ulcer is present.

Usefulness of FDG PET for diagnosis and radiotherapy of the patient with malignant lymphoma involving bone marrow

We experienced a case of relapsed malignant lymphoma with multiple bone marrow or bone lesions. The case was diagnosed as follicular lymphoma by cytological biopsy of the right iliac bone, with (67)Ga scintigraphy showing abnormal, intense uptake in multiple bones. After about 10 months of systemic chemotherapy, a relapse was suspected because of pain in the bilateral legs and a high level of lactate dehydrogenase. Assessment of the lesions in the patient was difficult by computed tomography because the affected sites were localized mainly in the bone marrow. (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) was useful for detecting accurately the relapse sites in the bone marrow and enabled us to determine the field for radiotherapy. There are only a few reports of FDG-PET findings for such bone marrow malignant lymphomas. Therefore, we report the findings of FDG-PET for this case and review some of the literature about bone marrow lymphomas.

False‐positive FDG–PET findings due to bone metastasis from prostate cancer in staging of non‐Hodgkin’s lymphoma

European Journal of HaematologyVolume 79, Issue 1 p. 88-90 False-positive FDG–PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin’s lymphoma Yuko Inoue, Yuko Inoue Departments of Gastroenterology and HepatologySearch for more papers by this authorHiroya Tamaki, Hiroya Tamaki MedicineSearch for more papers by this authorTamotsu Yamagami, Tamotsu Yamagami MedicineSearch for more papers by this authorHiroshi Iwasaki, Hiroshi Iwasaki UrologySearch for more papers by this authorShin-ichi Nakatsuka, Shin-ichi Nakatsuka Clinical Laboratory, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, JapanSearch for more papers by this authorToshihiro Soma, Toshihiro Soma Clinical Laboratory, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, JapanSearch for more papers by this author Yuko Inoue, Yuko Inoue Departments of Gastroenterology and HepatologySearch for more papers by this authorHiroya Tamaki, Hiroya Tamaki MedicineSearch for more papers by this authorTamotsu Yamagami, Tamotsu Yamagami MedicineSearch for more papers by this authorHiroshi Iwasaki, Hiroshi Iwasaki UrologySearch for more papers by this authorShin-ichi Nakatsuka, Shin-ichi Nakatsuka Clinical Laboratory, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, JapanSearch for more papers by this authorToshihiro Soma, Toshihiro Soma Clinical Laboratory, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, JapanSearch for more papers by this author First published: 10 April 2007 https://doi.org/10.1111/j.1600-0609.2007.00867.xCitations: 2 Dr Hiroya Tamaki, Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. Tel: 81 798 45 6886; Fax: 81 798 45 6887;e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Citing Literature Volume79, Issue1July 2007Pages 88-90 RelatedInformation